OIM
ADAP

Oracle Investment Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Oracle Investment Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-52,921
Closed -$304K – 19
2018
Q4 		$304K Sell
52,921
-844,573
-94% -$6.23M 0.09% 16
2018
Q3 		$12.2M Sell
897,494
-496,249
-36% -$5.2M 2.68% 8
2018
Q2 		$16.5M Buy
1,393,743
+63,673
+5% +$794K 4.04% 6
2018
Q1 		$14.9M Buy
1,330,070
+297,349
+29% +$2.6M 3.66% 7
2017
Q4 		$6.9M Buy
1,032,721
+330,860
+47% +$2.56M 1.38% 10
2017
Q3 		$5.75M Buy
+701,861
New +$4.38M 0.95% 12

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $48.2B AUM 24.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return